相关实验视频

Updated: Jan 9, 2026

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

化学性MHC类I和II受限制的非自我表位扩大抗瘤T细胞反应

Rongsheng Zhang¹, Rong Ma^1,2,3, Merrin M L Leong¹

¹Department of Immunology and Genomic Medicine, Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

The Journal of experimental medicine

|December 5, 2025

概括

完整的T细胞抗原 (CTA) 是化学,扩大T细胞对瘤新抗原的反应. 通过抑制CD8+T细胞耗尽和改善癌症预后,CTA治疗可以增强抗瘤免疫力.

科学领域:

免疫学免疫学免疫学
癌症生物学癌症生物学
分子生物学分子生物学

背景情况:

一种非自身抗原如何增强T细胞对另一种抗原的反应的机制尚未完全理解.
免疫反应可以通过非自身的化学来增强,称为完整的T细胞抗原 (CTA).

研究的目的:

研究CTAs在增强T细胞免疫反应中的作用.
阐明CTA增强抗瘤免疫力的机制.
探索CTA在癌症预后和治疗中的临床相关性.

主要方法:

识别和描述完整的T细胞抗原 (CTA) 作为MHC类I和II限制表位的单链仿真体.
用CTA作为活细胞辅助剂或通过cDNA转移的肌肉来评估T细胞对瘤新抗原的反应性.
在CTA治疗后的瘤中分析树突细胞表型,CD8+ T细胞枯竭和CD8+ T细胞生成.
癌症中CTA表达与框架转移突变与患者预后和对PD-1阻断疗法的反应的相关性.

主要成果:

当使用CTA时,T细胞对瘤新抗原的反应性会增加,即使与瘤抗原无关.
CTA治疗以 CD4+ T 细胞依赖的方式调节树突细胞表型.
摄入CTA抑制了CD8+T细胞的消耗,并促进了瘤内产生自我更新的CD8+T细胞.
具有框架转移突变的癌症,通常含有CTA,在临床前和临床环境中显示出更好的预后和更好的响应PD-1阻断疗法.

结论:

通过扩大T细胞对其他新抗原的反应,CTA足以诱导整体抗瘤免疫力.
癌细胞的一个子集中CTAs的表达可以引起更广泛的抗瘤免疫反应.
CTAs代表了一种潜在的治疗策略,通过克服T细胞耗尽和改善治疗结果来增强癌症免疫疗法.

更多相关视频

Peptide:MHC Tetramer-based Enrichment of Epitope-specific T cells

Peptide:MHC Tetramer-based Enrichment of Epitope-specific T cells

Published on: October 22, 2012

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

相关概念视频

Antigens Involved in Adaptive Immunity

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cross-reactivity

Cross-reactivity